Medicare Part D Fraud: The Pharmacy Claim Is Only the Beginning

Medicare Part D fraud includes billing for drugs never dispensed, false prescription data, concealed rebates or knowingly keeping federal overpayments. The conduct can begin at a pharmacy and reach Medicare through a drug plan’s reports and payment calculations. If you work behind the pharmacy counter, process claims for a pharmacy benefit manager or review a sponsor’s accounts, you may see the contradiction: a prescription recorded as dispensed, a rebate recorded as a service fee, or a correction that never reaches the money. Those connections are where a whistleblower case takes shape. Taxpayers fund prescriptions that never reach the patient.

Who Pays for a Part D Prescription?

Part D provides outpatient prescription drug coverage through private plans. The plan sponsor contracts with the Centers for Medicare & Medicaid Services and receives beneficiary premiums and federal payments. A pharmacy benefit manager may handle delegated work for the sponsor, while the pharmacy dispenses the drug and submits its claim.

That creates several accounts of the same prescription. The prescriber supplies the order. The pharmacy has dispensing and payment records. A claims processor handles the transaction. The sponsor reports drug-event and cost information to Medicare. Manufacturers supply rebates and other price concessions that can change the cost ultimately reported. Someone working with one of those records may know something the next participant never sees.

Drug coverage also depends on the payment path. Part B covers certain drugs, including specified clinician-administered drugs and qualifying pump insulin. Other covered outpatient insulin falls under Part D. Under the Medicare drug benefit guidance, how and where the drug is used determines which part of Medicare pays.

Medicare Part D Fraud Within MA-PD

Medicare Part D fraud within MA-PD concerns the prescription benefit inside a Medicare Advantage plan that combines medical and drug coverage. Its drug-event reporting and rebates still follow the Part D payment system. Part C’s advance payments and diagnosis-based risk adjustment have their own records and calculations. For a healthcare insider at a combined plan, identifying which payment the disputed data affected is the starting point.

Part D Prescription Claim Versus Federal False Claim

A pharmacy claim reaches federal payment through the sponsor’s reports and certifications to Medicare. A false dispensing record can feed a prescription drug event, reported drug costs or a certification used to obtain federal money. The False Claims Act reaches knowingly false payment requests, false records that matter to payment and knowing avoidance of money owed back to the government.

Medicare pays sponsors in advance, using their bids and other payment inputs, then reconciles those payments with the year’s reported costs.

During the year, prescription drug event data, usually called PDE data, records covered drug costs and the amounts attributed to different payers. Submissions can be accepted, rejected, adjusted or deleted. Those versions show what the sponsor told Medicare as its account of the prescription changed.

Direct and indirect remuneration, usually called DIR, captures concessions that reduce drug costs. Rebates belong in that picture, along with other qualifying price concessions. In annual reconciliation, the Centers for Medicare & Medicaid Services compares the relevant actual costs and subsidies with its advance payments.

The CMS instructions for the 2025 benefit year give a simplified example. For one drug category, the calculation starts with $400 in catastrophic drug costs, allocates $120 of DIR to those costs and applies the federal share to produce $56 of reinsurance. The agency then reconciles the calculated reinsurance with the advances already made to the plan.

The practical point is what a concealed rebate can do. If the reported cost leaves out a required concession, Medicare’s share is calculated against an inflated cost. We follow the prescription, the reported cost and the reconciliation together to understand that federal payment.

Medicare Sponsor Responsibility for Pharmacy Data

Medicare sponsor responsibility for pharmacy data continues when a pharmacy benefit manager performs delegated functions. The sponsor retains ultimate responsibility under its contract with the Centers for Medicare & Medicaid Services.

The pharmacy’s dispensing record, the processor’s transaction and the sponsor’s certification answer different questions. The first concerns what reached the patient. The next concerns the claim and its processing. The certification connects the submitted information to Medicare payment. Contractors generating claims data also have certification duties.

The Centers for Medicare & Medicaid Services’ attestation memorandum for the 2025 payment year distinguishes Summary DIR used for payment from Detailed DIR used in the branded-drug manufacturer fee process. The useful comparison is the money received, its treatment in the relevant dataset and what the sponsor certified.

Responsibility also follows the decisions inside the business. Who chose the data, who sent it, who was warned and who controlled the resulting payment can be different people. We work through those roles with the insider who knows how the transaction actually moved.

Prescriptions Billed but Never Dispensed

An uncollected prescription can leave both a dispensing discrepancy and a paid claim. The evidence connects the order, pickup or delivery, any reversal and the payment retained. A pharmacy worker may know the drug stayed behind while the billing records continued to describe a completed transaction.

In the Walgreens case, the government alleged that the company processed prescriptions that patients never picked up and that were never delivered, then retained payments. The Part D settlement agreement covered conduct from June 2013 through May 2020 and set a total of $97,814,791, including prior refunds. The prescription’s physical destination and the payer’s money were the connected questions.

In New York, a criminal indictment charged that a pharmacy operator billed for drugs never dispensed or induced by kickbacks, with claims exceeding wholesaler purchases. The indictment’s account puts purchasing records beside dispensing claims. It describes an alleged scheme involving Medicare and other payers. For someone who knows the pharmacy’s inventory, the amount purchased can expose a contradiction in the amount billed.

The DaVita Rx settlement addressed dispensing and copayment allegations. Its $63.7 million total included approximately $22.2 million already repaid. And there was still more to resolve. We examine what the company corrected, what it repaid and what the later settlement addressed.

False Prescription Drug Event Data

False Medicare Part D event data can misstate the prescription information that a sponsor submits to the Centers for Medicare & Medicaid Services. Prescriber identifiers, accepted records and later adjustments can show how a pharmacy transaction became a federal payment input. The important connection is between the disputed field and the payment decision it affected.

An analyst may see rejected events resubmitted, identifiers changed or adjustments entered after the original submission. We connect that history to the source prescription, the reporting instructions and the certification. A record of who directed a change can explain why the submitted data departed from the underlying transaction.

Rebates Reported as Service Fees

Medicare Part D rebate reporting fraud can conceal concessions by labeling retained manufacturer rebates as service fees. The federal consequence comes through the sponsor’s reported drug costs and reconciliation. The contract description, work actually performed and money retained belong beside the DIR report.

Rite Aid and Elixir Insurance Company agreed in July 2024 to a $101 million settlement obligation over allegedly false rebate reporting. The government alleged that retained manufacturer rebates appeared as bona fide service fees on Elixir’s reports even though they did not qualify for that treatment.

The whistleblower’s complaint made the alleged absence of services explicit. It referred to the business retaining the rebates as EPS:

We see the absurdity in that allegation: a fee for services nobody performed. The label supplied the explanation for keeping the rebate. For someone in rebate accounting, contracting or sponsor reporting, the connection between the manufacturer’s payment and the treatment on the federal report is the heart of the matter.

Medicare Part D Overpayments Kept After Identification

Knowingly keeping a Part D overpayment past the return deadline can trigger a False Claims Act case. The question reaches what the business learned about its entitlement to the money and what it did next.

A warning, an investigation, a calculation and a refund mark different points in that story. A plan employee may see the amount quantified while the corresponding report or repayment remains unresolved. A change in future submissions also leaves the earlier payment history to examine.

We work through the reconciliation and repayment history with Medicare Part D whistleblower counsel so the case follows the rule governing the money at issue.

What the Data Shows and What the Insider Explains

Claims analysis can identify patterns worth examining across a provider’s prescribing, health care services and equipment activity. An insider can explain the decisions behind the pattern, including who changed a record or continued a practice after a warning.

Big Data fraud detection using multiple medicare data sources, published in the Journal of Big Data in 2018, combined Part B, Part D and durable medical equipment data. The study recommended using the combined dataset when a provider’s payment records span the Medicare parts it examined.

The journal’s 2023 paper, Explainable machine learning models for Medicare fraud detection, found that using fewer inputs improved classification in its Part D experiment. For us, the next connection is to the particular prescription, report, instruction or payment that explains the signal.

The CMS Part D payment-error estimate for fiscal 2025 measured payments from calendar 2023. Its gross estimate was $4.23 billion, or 4.00%, counting both overpayments and underpayments.

Oversight reaches beyond identifying a suspect transaction. In January 2026, the Department of Health and Human Services’ Office of Inspector General announced a review of pharmacy fraud controls, asking whether pharmacies identified as bad actors by CMS or plan sponsors continued billing and receiving Part D payments. The announced review focuses on the effectiveness of controls and opportunities to improve detection. Its question goes directly to what an insider may see after a problem has already been raised.

The Records Behind a Part D Whistleblower Case

The useful Medicare fraud evidence connects what happened to the prescription with what the business told the payer. Dispensing staff may understand pickup, delivery and reversals. A pharmacy benefit manager’s analyst may understand claim processing and changes to event data. A sponsor’s finance or rebate team may understand the cost reports, certifications and reconciliation.

Warnings and responses connect those records to knowledge. The dated concern, the recipient’s response and subsequent submissions can show whether a disputed practice continued after someone inside identified it. Payment and refund records show where that decision left the money. We bring those accounts together with you, starting with the work you know firsthand.

Do You Get a Reward for Reporting Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We work with you on confidentiality and your position inside the business as part of building the case.

When You Know Why the Numbers Changed

If you know why a prescription, rebate or correction tells a different story in the payment records, talk with our whistleblower experts about the Part D money behind it. We work beside you to build your strongest case and bring in Medicare Part D fraud whistleblower lawyers who understand the path from dispensing to federal reconciliation. You bring the inside knowledge, and we stay with you through the case.